Gadolinium Retention Warnings Added To Drug Labels For Gadolinium Contrast Agents Used During MRI / MRA

Label Changes Announced By FDA In December 2017 Finally Approved For Magnevist, Omniscan, And Other GBCAs In April 2018   (Posted by Tom Lamb at DrugInjuryWatch.com)   Gadolinium based contrast agents (GBCAs) are substances that are injected into patients during a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images. Over the past couple of years drug regulators around the world have started to pay attention to so-called "side effect" of certain GBCAs called Gadolinium Deposition Disease (GDD), which is a form of gadolinium toxicity and sometimes called, instead, Gadolinium Storage Condition. However, as seen from the following excerpt from our December 2017 article "Gadolinium-Containing Contrast Agents Omniscan And Magnevist Being Recalled In The United Kingdom In February 2018", the actions taken by the FDA are different from what is being done by some other regulators: In…

Read more detail on Recent Health Care Law posts –

This entry was posted in Health Law and tagged , , , , , , , , , . Bookmark the permalink.

Leave a Reply